id: NEW:phenobarbital_treatment_aws_to_NEW:intubation_rate_aws
name: Phenobarbital Treatment for Alcohol Withdrawal Syndrome â†’ Intubation Rate in
  AWS Patients
from_node:
  node_id: NEW:phenobarbital_treatment_aws
  node_name: Phenobarbital Treatment for Alcohol Withdrawal Syndrome
to_node:
  node_id: NEW:intubation_rate_aws
  node_name: Intubation Rate in AWS Patients
direction: negative
category: healthcare_access
mechanism_pathway:
- 'Step 1: Patients with chronic/heavy alcohol consumption develop Alcohol Withdrawal
  Syndrome (AWS) requiring medical intervention in ED/ICU settings'
- 'Step 2: Phenobarbital is administered as treatment for AWS, acting on GABA receptors
  with a longer half-life and different pharmacological profile than benzodiazepines'
- 'Step 3: Phenobarbital''s mechanism of action provides CNS depression and anticonvulsant
  effects, potentially offering smoother withdrawal management'
- 'Step 4: Treatment aims to reduce severe AWS complications including respiratory
  failure requiring intubation'
- 'Step 5: Meta-analysis shows phenobarbital associated with numerically lower (but
  not statistically significant) intubation rates compared to standard benzodiazepine
  treatment (RR 0.70)'
evidence:
  quality_rating: A
  n_studies: 12
  primary_citation: 'Ali Pourmand et al. 2023. Evaluation of phenobarbital based approach
    in treating patient with alcohol withdrawal syndrome: A systematic review and
    meta-analysis. The American journal of emergency medicine.'
  supporting_citations: []
description: This meta-analysis of 12 studies (1934 patients) examined whether phenobarbital
  treatment for Alcohol Withdrawal Syndrome affects intubation rates compared to benzodiazepine
  treatment. Results showed a non-significant trend toward lower intubation risk with
  phenobarbital (RR 0.70, 95% CI 0.36-1.38, P=0.31). While the point estimate suggests
  a 30% relative reduction in intubation risk, the wide confidence interval crossing
  1.0 indicates uncertainty about the true effect. The negative direction is supported
  by the point estimate but not statistically confirmed.
last_updated: '2025-12-02'
extraction_method: consolidated_batch_v3
quantitative_effects:
  effect_size:
    value: 0.7
    type: relative_risk
    ci_lower: 0.36
    ci_upper: 1.38
  p_value: 0.31
  sample_size: 1934
moderators:
- name: Treatment setting (ED vs ICU)
  direction: strengthens
  strength: weak
  description: Both ED and ICU settings were included; effect may vary by acuity of
    care setting
- name: Study design
  direction: weakens
  strength: moderate
  description: Mostly observational studies included, limiting causal inference strength
